在一项研究中,Skinvisible Pharmaceuticals宣布通过皮肤进行的无贴片或针的999. 6%有效的血糖控制. Skinvisible Pharmaceuticals announces 99.6% effective transdermal glucose control without patches or needles in a study.

皮肤可见药品公司已公布其通过皮肤输送的系统Invisicare®的研究结果,该系统有效地在没有贴片或针的情况下输送血糖控制剂. Skinvisible Pharmaceuticals has published findings on its transdermal delivery system, Invisicare®, which effectively administers glucose-controlling agents without patches or needles. 研究表明,六小时以上GLP-1制剂的交付率为99.6%,令人瞩目。 The study showed a remarkable 99.6% delivery rate for GLP-1 formulations over six hours. 这种方法可以加强病人的合规性,减少与口服药物有关的副作用。 This method may enhance patient compliance and reduce side effects linked to oral medications. 该公司寻求伙伴关系,推进转基因肥胖症治疗,并探索其技术的更广泛应用。 The company seeks partnerships to advance transdermal obesity therapies and explore wider applications of its technology.